Proteasome Inhibition in Transplantation-Focusing on the Experience with Bortezomib

E-ISSN： 1873-4286|19|18|3299-3304

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.18, 2013-06, pp. : 3299-3304

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib: Proteasome Inhibition as a Novel Mechanism of Cancer Therapy-Implications for Hematological Malignancies

Letters in Drug Design & Discovery, Vol. 4, Iss. 2, 2007-03 ,pp. : 82-86

Bentham Science Publishers

Access to resources Recommend Favorite

A review of the proteasome inhibitor bortezomib in multiple myeloma

By Richardson Paul G

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 6, 2004-06 ,pp. : 1321-1331

Informa Healthcare

Access to resources Recommend Favorite

From Bortezomib to other Inhibitors of the Proteasome and Beyond

Current Pharmaceutical Design, Vol. 19, Iss. 22, 2013-07 ,pp. : 4025-4038

Bentham Science Publishers

Access to resources Recommend Favorite

The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib

Current Pharmaceutical Design, Vol. 17, Iss. 15, 2011-05 ,pp. : 1483-1499

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition

Current Pharmaceutical Design, Vol. 19, Iss. 22, 2013-01 ,pp. : 4053-4093

Bentham Science Publishers

Access to resources Recommend Favorite